UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics Pharmaceuticals, a leading innovator in the development of novel therapeutics for endocrine diseases and cancers, is set to debut significant advancements from its pipeline at the 2023 North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. The event will take place from October 19-21, 2023, in Houston, Texas.
In a notable highlight, Crinetics will introduce its proprietary nonpeptide drug conjugate platform, which has the potential to revolutionize the treatment landscape for neuroendocrine tumors (NETs). This cutting-edge technology is designed to improve the specificity and efficacy of drug delivery, targeting SST2-expressing tumors with unprecedented precision.
Central to this showcase will be the preclinical profile of Crinetics lead candidate, CRN09682. This innovative compound has been engineered to bind to somatostatin receptor 2 (SST2), a key biomarker in various neuroendocrine tumors. The data presented at the NANETS meeting are expected to underscore CRN09682’s promising therapeutic potential, demonstrating its ability to effectively inhibit tumor growth while minimizing off-target effects.
As part of its strategic roadmap, Crinetics is on track to submit an Investigational New Drug (IND) application for CRN09682 in early 2025. This marks a significant milestone in the company’s commitment to advancing treatments aimed at improving the lives of patients with NETs, a group of rare but increasingly recognized tumors that can impact various organs and often lead to complex clinical challenges.
“We are excited to present our innovative nonpeptide drug conjugate platform and the preclinical results for CRN09682 at this year’s NANETS Annual Meeting,” said Dr. Richard I. M. B. Moreau, Chief Executive Officer of Crinetics Pharmaceuticals. “This opportunity allows us to engage directly with experts in the field, share our advancements, and explore potential collaborations that may accelerate the development of vital therapies for neuroendocrine tumors.”
As the awareness and understanding of NETs grow, so too does the need for effective treatments. The upcoming NANETS meeting is expected to draw leading researchers, clinicians, and industry stakeholders, providing an invaluable platform for dialogue and knowledge exchange. Crinetics presence will not only highlight their innovative research but also reinforce the importance of targeting specific pathways in the fight against NETs.
Attendees can look forward to insightful presentations and discussions on the future of neuroendocrine tumor therapies, positioning Crinetics Pharmaceuticals as a key player in this rapidly evolving therapeutic area.
Stay tuned for further updates from the conference and Crinetics Pharmaceuticals as they continue to make strides toward transforming the management of neuroendocrine tumors through cutting-edge science and innovation.
Comments